Hepatic molecular responses to Bifidobacterium pseudocatenulatum CECT 7765 in a mouse model ofdiet-induced obesity

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 1, 2014, Pages 57-64

  Moya Perez A ^a   Romo Vaquero, M ^b   Tomas Barberan F ^b   Sanz, Y ^a   Garcia Conesa M T ^b  

^a INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^b RESEARCH GROUP ON QUALITY   (Spain)

Author keywords

APOA4; CD36; EGR1; FABP5; Gene expression; HFD; HMGCR; IGFBP2; INSIG1; Lipid metabolism; Liver; PNPLA2; PPARA; PPARGC1A; PPP1R3B; Probiotic; SD; TAGs; Transcriptome

Indexed keywords

APOLIPOPROTEIN A4; CD36 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 1 REGULATORY SUBUNIT 3B; SOMATOMEDIN BINDING PROTEIN 2; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM; BIFIDOBACTERIUM PSEUDOCATENULATUM; COLONY FORMING UNIT; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; ENERGY METABOLISM; GENE; GENE EXPRESSION; INSULIN INDUCED GENE 1; LIPID DIET; LIPID TRANSPORT; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; OBESITY; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 2; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRAVIOLET SPECTROPHOTOMETRY;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; BIFIDOBACTERIUM PSEUDOCATENULATUM; MUS;

GENE EXPRESSION; LIPID METABOLISM; LIVER; PROBIOTIC; TRANSCRIPTOME;

ANIMALS; BIFIDOBACTERIUM; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 1; FATTY ACIDS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LIPASE; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; OBESITY; PROBIOTICS; PROTEIN PHOSPHATASE 1; RNA, MESSENGER; TRANSCRIPTOME; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84894225450     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.04.011     Document Type: Article

References (29)

1. Nguyen T., Lau D.C. The obesity epidemic and its impact on hypertension. Can J Cardiol 2012, 28:326-333.
2. Tagliabue A., Elli M. The role of gut microbiota in human obesity: recent findings and future perspectives. Nutr Metab Cardiovasc Dis 2013, 23:160-168.
3. Million M., Angelakis E., Paul M., Armougom F., Leibovici L., Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog 2012, 53:100-108.
4. Sanz Y., Rastmanesh R., Agostonic C. Understanding the role of gut microbes and probiotics in obesity: how far are we?. Pharmacol Res 2012, pii: S1043-6618(12)00208-3. doi:10.1016/j.phrs.2012.10.021.
5. Delzenne N.M., Neyrinck A.M., Cani P.D. Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microb Cell Fact 2011, 10:S10.
6. Fåk F., Bäckhed F. Lactobacillus reuteri prevents diet-induced obesity, but not Atherosclerosis, in a strain dependent fashion in Apoe-/- mice. PLoS One 2012, 7:e46837.
7. Angelakis E., Bastelica D., Ben Amara A., El Filali A., Dutour A., Mege J.L., et al. An evaluationof the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microb Pathog 2012, 52:61-68.
8. Chen J., Wang R., Li X.F., Wang R.L. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr 2011, 107:1429-1434.
9. An H.M., Park S.Y., Lee do K., Kim J.R., Cha M.K., Lee S.W., et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 2011, 10:116.
10. Gauffin P., Santacruz A., Trejo F.M., Sanz Y. Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet fed mice. Obesity 2013, doi:10.1002/oby.20330.
11. Compare D., Coccoli P., Rocco A., Nardone O.M., De Maria S., Carteni M., et al. Gut-liver axis: the impact of gut microbiota on non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012, 22:471-476.
12. Cani P.D., Delzenne N.M. The gut microbiome as therapeutic target. Pharmacol Ther 2011, 130:202-212.
13. Iacono A., Raso G.M., Canani R.B., Calignano A., Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011, 22:699-711.
14. Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001, 161. III-XIII, 1-151.
15. Do G.M., Oh H.Y., Kwon E.Y., Cho Y.Y., Shin S.K., Park H.J., et al. Long-term adaptation of global transcription and metabolism in the liver of high-fat diet-fed C57BL/6J mice. Mol Nutr Food Res 2011, 55:S173-S185.
16. Nishikawa S., Sugimoto J., Okada M., Sakairi T., Takagi S. Gene expression in livers of BALB/C and C57BL/6J mice fed a high-fat diet. Toxicol Pathol 2012, 40:71-82.
17. He J., Lee J.H., Febbraio M., Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med 2011, 236:1116-1121.
18. Gokey N.G., Lopez-Anido C., Gillian-Daniel A.L., Svaren J. Early growth response 1 (Egr1) regulates cholesterol biosynthetic gene expression. J Biol Chem 2011, 286:29501-29510.
19. Burg J.S., Espenshade P.J. Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res 2011, 50:403-410.
20. Steinmetz A., Schneider W.J. Evolving functions of apolipoprotein AIV: from birds to mammals. Trends Cardiovasc Med 1999, 9:153-157.
21. Zhao X., Higashikawa F., Noda M., Kawamura Y., Matoba Y., Kumagai T., et al. The obesity and fatty liver are reduced by plant-derived Pediococcuspentosaceus LP28 in high fat diet-induced obese mice. PLoS One 2012, 7:e30696.
22. Turpin S.M., Hoy A.J., Brown R.D., Rudaz C.G., Honeyman J., Matzaris M., et al. Adiposetriacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia 2011, 54:146-156.
23. Jeun J., Kim S., Cho S.Y., Jun H.J., Park H.J., Seo J.G., et al. Hypocholesterolemic effects of Lactobacillus plantarum KCTC3928 by increased bile acid excretion in C57BL/6 mice. Nutrition 2010, 26:321-330.
24. Wheatcroft S.B., Kearney M.T. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009, 20:153-162.
25. Luo X., Zhang Y., Ruan X., Jiang X., Zhu L., Wang X., et al. Fasting-inducedprotein phosphatase 1 regulatory subunit contributes to postprandial blood glucose homeostasis via regulation of hepatic glycogenesis. Diabetes 2011, 60:1435-1445.
26. Shuldiner A.R., Pollin T.I. Variationsin blood lipids. Nature 2011, 466:703-704.
27. Speliotes E.K., Yerges-Armstrong L.M., Wu J., Hernaez R., Kim L.J., Palmer C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 3:e1001324.
28. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomicanalyses. Nat Rev Genet 2012, 13:227-232.
29. Pachikian B.D., Essaghir A., Demoulin J.B., Catry E., Neyrinck A.M., Dewulf E.M., et al. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. Mol Nutr Food Res 2012, doi:10.1002/mnfr.201200364.